Zheng Heqing, Wu Lanxiang, Tian Sheng, Liu Mingxu, Zhan Qingqing, Yu Xinping, Xie Yonggang, Zhong Xianhui, Wu Wei
Department of Neurology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Front Neurol. 2023 Feb 9;14:1115482. doi: 10.3389/fneur.2023.1115482. eCollection 2023.
It has been shown in previous studies that botulinum toxin type A (BTX-A) can effectively relieve the motor symptoms of Meige syndrome. However, its effect on non-motor symptoms (NMS) and quality of life (QoL) has not been comprehensively studied. This study aimed to explore the effects of BTX-A on NMS and QoL and to clarify the relationship between changes in motor symptoms, NMS, and QoL after BTX-A.
Seventy-five patients were recruited for the study. All patients were assessed by a series of clinical assessments before, one, and 3 months after BTX-A treatment. Dystonic symptoms, psychiatric disturbances, sleep disorders, and QoL were evaluated.
After 1 and 3 months of BTX-A treatment, the scores of motor symptoms, anxiety, and depression were significantly decreased ( < 0.05). Except for general health, the scores of the other 36-item short-form health survey QoL subitems were significantly improved after BTX-A ( < 0.05). After 1 month of treatment, the changes in anxiety and depression were not correlated with changes in motor symptoms ( > 0.05). Still, they were negatively correlated with changes in physical functioning, role-physical and mental component summary QoL ( < 0.05).
BTX-A effectively improved motor symptoms, anxiety, depression, and QoL. Anxiety and depression improvement did not correlate with motor symptom changes after BTX-A, and QoL improvements were strongly associated with psychiatric disturbances.
既往研究表明，A型肉毒毒素（BTX-A）可有效缓解Meige综合征的运动症状。然而，其对非运动症状（NMS）和生活质量（QoL）的影响尚未得到全面研究。本研究旨在探讨BTX-A对NMS和QoL的影响，并阐明BTX-A治疗后运动症状、NMS和QoL变化之间的关系。
招募75例患者进行研究。所有患者在BTX-A治疗前、治疗后1个月和3个月接受一系列临床评估。评估肌张力障碍症状、精神障碍、睡眠障碍和QoL。
BTX-A治疗1个月和3个月后，运动症状、焦虑和抑郁评分显著降低（<0.05）。BTX-A治疗后，除总体健康外，36项简短健康调查QoL子项目中的其他项目评分均显著改善（<0.05）。治疗1个月后，焦虑和抑郁的变化与运动症状的变化无相关性（>0.05）。然而，它们与身体功能、角色-身体和心理成分总结QoL的变化呈负相关（<0.05）。
BTX-A有效改善了运动症状、焦虑、抑郁和QoL。BTX-A治疗后焦虑和抑郁的改善与运动症状变化无关，QoL的改善与精神障碍密切相关。
